Cargando…

Sensory neuropathy hampers nociception-mediated bone marrow stem cell release in mice and patients with diabetes

AIMS/HYPOTHESIS: Upon tissue injury, peripheral sensory neurons release nociceptive factors (e.g. substance P [SP]), which exert local and systemic actions including the recruitment of bone marrow (BM)-derived haematopoietic stem and progenitor cells (HSPCs) endowed with paracrine pro-angiogenic pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dang, Zexu, Maselli, Davide, Spinetti, Gaia, Sangalli, Elena, Carnelli, Franco, Rosa, Francesco, Seganfreddo, Elena, Canal, Fabio, Furlan, Anna, Paccagnella, Agostino, Paiola, Emanuela, Lorusso, Bruno, Specchia, Claudia, Albiero, Mattia, Cappellari, Roberta, Avogaro, Angelo, Falco, Angela, Quaini, Federico, Ou, Kepeng, Rodriguez-Arabaolaza, Iker, Emanueli, Costanza, Sambataro, Maria, Fadini, Gian Paolo, Madeddu, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589553/ https://www.ncbi.nlm.nih.gov/pubmed/26358583 http://dx.doi.org/10.1007/s00125-015-3735-0

Ejemplares similares

MicroRNA-21/PDCD4 Proapoptotic Signaling From Circulating CD34(+) Cells to Vascular Endothelial Cells: A Potential Contributor to Adverse Cardiovascular Outcomes in Patients With Critical Limb Ischemia
por: Spinetti, Gaia, et al.
Publicado: (2020)

The dipeptidyl peptidase-4 inhibitor Saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients
por: Poncina, Nicol, et al.
Publicado: (2014)

Prognostic Significance of Circulating and Endothelial Progenitor Cell Markers in Type 2 Diabetic Foot
por: Sambataro, Maria, et al.
Publicado: (2014)

Diabetes Impairs Stem Cell and Proangiogenic Cell Mobilization in Humans
por: Fadini, Gian Paolo, et al.
Publicado: (2013)

Hematopoietic progenitor cell liabilities and alarmins S100A8/A9‐related inflammaging associate with frailty and predict poor cardiovascular outcomes in older adults
por: Bonora, Benedetta Maria, et al.
Publicado: (2022)

Endothelial Dysfunction in Diabetes: The role of reparatory mechanisms
por: Avogaro, Angelo, et al.
Publicado: (2011)

Putative circulating adipose tissue-derived stem cells, obesity, and metabolic syndrome features
por: Bonora, B. M., et al.
Publicado: (2023)

Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor
por: Fadini, Gian Paolo, et al.
Publicado: (2015)

DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes
por: Fadini, Gian Paolo, et al.
Publicado: (2017)

Mitochondrial Calcium Uptake Is Instrumental to Alternative Macrophage Polarization and Phagocytic Activity
por: Tedesco, Serena, et al.
Publicado: (2019)

MicroRNA-532-5p Regulates Pericyte Function by Targeting the Transcription Regulator BACH1 and Angiopoietin-1
por: Slater, Sadie C., et al.
Publicado: (2018)

The expression of the BPIFB4 and CXCR4 associates with sustained health in long-living individuals from Cilento-Italy
por: Spinetti, Gaia, et al.
Publicado: (2017)

p66Shc gene expression in peripheral blood mononuclear cells and progression of diabetic complications
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Impaired Hematopoietic Stem/Progenitor Cell Traffic and Multi-organ Damage in Diabetes
por: Fadini, Gian Paolo, et al.
Publicado: (2022)

Improved prediction of long-term kidney outcomes in people with type 2 diabetes by levels of circulating haematopoietic stem/progenitor cells
por: Bonora, Benedetta Maria, et al.
Publicado: (2023)

Umbilical Cord Pericytes Provide a Viable Alternative to Mesenchymal Stem Cells for Neonatal Vascular Engineering
por: Cathery, William, et al.
Publicado: (2021)

Glycaemic Control Achieves Sustained Increases of Circulating Endothelial Progenitor Cells in Patients Hospitalized for Decompensated Diabetes: An Observational Study
por: Bonora, Benedetta Maria, et al.
Publicado: (2022)

It Is All in the Blood: The Multifaceted Contribution of Circulating Progenitor Cells in Diabetic Complications
por: Fadini, Gian Paolo, et al.
Publicado: (2012)

How to interpret the role of SDF-1α on diabetic complications during therapy with DPP-4 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Procalcific Phenotypic Drift of Circulating Progenitor Cells in Type 2 Diabetes with Coronary Artery Disease
por: Fadini, Gian Paolo, et al.
Publicado: (2012)

Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial
por: Fadini, Gian Paolo, et al.
Publicado: (2017)

The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes: Possible role of stromal-derived factor-1α
por: Fadini, Gian Paolo, et al.
Publicado: (2010)

Nerve growth factor gene therapy improves bone marrow sensory innervation and nociceptor-mediated stem cell release in a mouse model of type 1 diabetes with limb ischaemia
por: Dang, Zexu, et al.
Publicado: (2019)

Stem cell mobilization with plerixafor and healing of diabetic ischemic wounds: A phase IIa, randomized, double‐blind, placebo‐controlled trial
por: Bonora, Benedetta Maria, et al.
Publicado: (2020)

Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Managing diabetes in diabetic patients with COVID: where do we start from?
por: Avogaro, Angelo, et al.
Publicado: (2021)

The Peritoneum as a Natural Scaffold for Vascular Regeneration
por: Bonvini, Stefano, et al.
Publicado: (2012)

Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice
por: Morieri, Mario Luca, et al.
Publicado: (2020)

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
por: Bonora, Benedetta Maria, et al.
Publicado: (2020)

Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics
por: Morieri, Mario Luca, et al.
Publicado: (2020)

Response to Chia Siang Kow and colleagues
por: Avogaro, Angelo, et al.
Publicado: (2022)

Vascular Stem and Progenitor Cells in Diabetic Complications
por: Fadini, Gian Paolo, et al.
Publicado: (2012)

Fixed versus flexible combination of GLP‐1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study
por: Morieri, Mario Luca, et al.
Publicado: (2019)

A miR-125/Sirtuin-7 pathway drives the pro-calcific potential of myeloid cells in diabetic vascular disease
por: Vigili de Kreutzenberg, Saula, et al.
Publicado: (2022)

Treatment of COVID-19 by stage: any space left for mesenchymal stem cell therapy?
por: Spinetti, Gaia, et al.
Publicado: (2021)

Effects of androgens on endothelial progenitor cells in vitro and in vivo
por: Fadini, Gian Paolo, et al.
Publicado: (2009)

SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
por: Bonora, Benedetta Maria, et al.
Publicado: (2021)

Challenges and opportunities in real‐world evidence on the renal effects of sodium‐glucose cotransporter‐2 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2021)

Bone marrow pericyte dysfunction in individuals with type 2 diabetes
por: Mangialardi, Giuseppe, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_f8ohs8qe5g2o1qebmtkanifc32